GSK Emerges as Unexpected Winner From American Oncology Conference -- Market Talk

Dow Jones06-01

0953 GMT - U.K. drugmaker GSK came out as an unexpected winner from a big U.S. oncology conference, Jefferies analysts say in a note. Early-stage data for GSK's drug candidate IDRx-42 presented at the American Society of Clinical Oncology's annual meeting showed potential as a first-line treatment for gastrointestinal cancer, Jefferies says. Moreover, updates from rivals on new ovarian-cancer drugs didn't top those of GSK's own candidate Mo-Rez, the analysts say. Competition in the market for drugs to treat ovarian cancer resistant to platinum-based chemotherapy is heating up, they add. GSK's Mo-Rez and NaPi2b--developed by Tubulis, which was recently acquired by Gilead Sciences--might be setting the bar for the disease, while AstraZeneca's Puxi-Sam doesn't look as competitive, according to Jefferies. GSK shares fall 0.3%. (adria.calatayud@wsj.com)

(END) Dow Jones Newswires

June 01, 2026 05:53 ET (09:53 GMT)

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2640930291?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-06-01 17:53","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2640930291","market":"nz","top_or_hot":-1,"title":"GSK Emerges as Unexpected Winner From American Oncology Conference -- Market Talk","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<p>\n     0953 GMT - U.<a href=\"https://laohu8.com/S/TKKD.SI\">K</a>. drugmaker GSK came out as an unexpected winner from a big U.S. oncology conference, Jefferies analysts say in a note. Early-stage data for GSK's drug candidate IDRx-42 presented at the American Society of Clinical Oncology's annual meeting showed potential as a first-line treatment for gastrointestinal cancer, Jefferies says. Moreover, updates from rivals on new ovarian-cancer drugs didn't top those of GSK's own candidate Mo-Rez, the analysts say. Competition in the market for drugs to treat ovarian cancer resistant to platinum-based chemotherapy is heating up, they add. GSK's Mo-Rez and NaPi2b--developed by Tubulis, which was recently acquired by <a href=\"https://laohu8.com/S/GILD\">Gilead</a> Sciences--might be setting the bar for the disease, while AstraZeneca's Puxi-Sam doesn't look as competitive, according to Jefferies. GSK shares fall 0.3%. (adria.calatayud@wsj.com) \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  June 01, 2026 05:53 ET (09:53 GMT)\n</p>\n<p>\n  Copyright (c) 2026 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>GSK Emerges as Unexpected Winner From American Oncology Conference -- Market Talk</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nGSK Emerges as Unexpected Winner From American Oncology Conference -- Market Talk\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time\">2026-06-01 17:53</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<font class=\"NormalMinus1\" face=\"Arial\">\n<p>\n     0953 GMT - U.<a href=\"https://laohu8.com/S/TKKD.SI\">K</a>. drugmaker GSK came out as an unexpected winner from a big U.S. oncology conference, Jefferies analysts say in a note. Early-stage data for GSK's drug candidate IDRx-42 presented at the American Society of Clinical Oncology's annual meeting showed potential as a first-line treatment for gastrointestinal cancer, Jefferies says. Moreover, updates from rivals on new ovarian-cancer drugs didn't top those of GSK's own candidate Mo-Rez, the analysts say. Competition in the market for drugs to treat ovarian cancer resistant to platinum-based chemotherapy is heating up, they add. GSK's Mo-Rez and NaPi2b--developed by Tubulis, which was recently acquired by <a href=\"https://laohu8.com/S/GILD\">Gilead</a> Sciences--might be setting the bar for the disease, while AstraZeneca's Puxi-Sam doesn't look as competitive, according to Jefferies. GSK shares fall 0.3%. (adria.calatayud@wsj.com) \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  June 01, 2026 05:53 ET (09:53 GMT)\n</p>\n<p>\n  Copyright (c) 2026 Dow Jones &amp; Company, Inc.\n</p>\n</font>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4588","symbol_name":"碎股","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2640930291","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2640930291","pubTimestamp":1780307580,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"0953 GMT - U.K. drugmaker GSK came out as an unexpected winner from a big U.S. oncology conference, Jefferies analysts say in a note. Early-stage data for GSK's drug candidate IDRx-42 presented at the American Society of Clinical Oncology's annual meeting showed potential as a first-line treatment for gastrointestinal cancer, Jefferies says. Moreover, updates from rivals on new ovarian-cancer drugs didn't top those of GSK's own candidate Mo-Rez, the analysts say. Competition in the market for drugs to treat ovarian cancer resistant to platinum-based chemotherapy is heating up, they add. GSK's Mo-Rez and NaPi2b--developed by Tubulis, which was recently acquired by Gilead Sciences--might be setting the bar for the disease, while AstraZeneca's Puxi-Sam doesn't look as competitive, according to Jefferies. GSK shares fall 0.3%. ","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4588":"碎股","AFG":"美国金融集团有限公司","BK4117":"多元化保险","BK4585":"ETF&股票定投概念","GSK":"葛兰素史克","LU1829250122.USD":"高盛欧洲核心股票组合Acc","BK4107":"财产与意外伤害保险","GSK.UK":"葛兰素史克","BK4532":"文艺复兴科技持仓","BK4007":"制药","GSKH":"GSK plc ADRhedged"},"translate_title":"葛兰素史克出人意料地成为美国肿瘤学会议的赢家——市场谈话","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"GSKH":0.6,"AFG":1.5,"GSK":1.5,"GSK.UK":0.6},"content_text":"0953 GMT - U.K. drugmaker GSK came out as an unexpected winner from a big U.S. oncology conference, Jefferies analysts say in a note. Early-stage data for GSK's drug candidate IDRx-42 presented at the American Society of Clinical Oncology's annual meeting showed potential as a first-line treatment for gastrointestinal cancer, Jefferies says. Moreover, updates from rivals on new ovarian-cancer drugs didn't top those of GSK's own candidate Mo-Rez, the analysts say. Competition in the market for drugs to treat ovarian cancer resistant to platinum-based chemotherapy is heating up, they add. GSK's Mo-Rez and NaPi2b--developed by Tubulis, which was recently acquired by Gilead Sciences--might be setting the bar for the disease, while AstraZeneca's Puxi-Sam doesn't look as competitive, according to Jefferies. GSK shares fall 0.3%. (adria.calatayud@wsj.com) \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  June 01, 2026 05:53 ET (09:53 GMT)\n\n\n  Copyright (c) 2026 Dow Jones & Company, Inc.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"merge","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":true,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.43.1","shortVersion":"4.43.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2640930291","isCrawlerRequest":true}